Edition:
United Kingdom

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

18.36USD
16 Aug 2018
Change (% chg)

$0.14 (+0.77%)
Prev Close
$18.22
Open
$18.18
Day's High
$18.90
Day's Low
$18.13
Volume
17,280
Avg. Vol
35,255
52-wk High
$23.36
52-wk Low
$5.59

Select another date:

Wed, May 30 2018

Photo

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million (75.5 million pounds) deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

Deutsche Boerse beefs up forex business with $100 mln buy

BERLIN, May 30 Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

BRIEF-GTX Inc Q4 Loss Per Share $0.43

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

* GTX ANNOUNCED NEW DATA DEMONSTRATING ENOBOSARM’S POTENTIAL TO TREAT STRESS URINARY INCONTINENCE AT SUFU 2018

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage:

Select another date: